Original Article

You have full text access to this OnlineOpen article

Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy

  1. Douglas S. Hawkins M.D.1,†,*,
  2. Carola A. S. Arndt M.D.2

Article first published online: 14 OCT 2003

DOI: 10.1002/cncr.11799

Issue

Cancer

Cancer

Volume 98, Issue 11, pages 2447–2456, 1 December 2003

Additional Information

How to Cite

Hawkins, D. S. and Arndt, C. A. S. (2003), Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer, 98: 2447–2456. doi: 10.1002/cncr.11799

Author Information

  1. 1

    Department of Pediatrics, Children's Hospital and Regional Medical Center, Seattle, Washington

  2. 2

    Department of Pediatrics, Mayo Clinic, Rochester, Minnesota

  1. †

    Fax: (206) 987-3946

*Department of Pediatrics, Children's Hospital and Regional Medical Center, MS: 6D-1, 4800 Sand Point Way, Seattle, WA 98105

Publication History

  1. Issue published online: 17 NOV 2003
  2. Article first published online: 14 OCT 2003
  3. Manuscript Accepted: 26 AUG 2003
  4. Manuscript Revised: 6 AUG 2003
  5. Manuscript Received: 15 MAY 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (176K)

REFERENCES

  • 1
    Gurney JG, Swensen AR, Bulterys M. Malignant bone tumors. In: RiesLAG, SmithMA, GurneyJG, et al., editors. Cancer incidence and survival among children and adolescents: United States SEER program 1975-1995. National Cancer Institute, SEER Program. NIH Pub. No. 99-4649. Besthesda, MD: National Cancer Institute, 1999: 99–110.
  • 2
    Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986; 314: 1600–1606.
  • 3
    Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin North Am. 1997; 44: 973–989.
  • 4
    Martini N, Huvos AG, Mike V, Marcove RC, Beattie EJ Jr. Multiple pulmonary resections in the treatment of osteogenic sarcoma. Ann Thorac Surg. 1971; 12: 271–280.
  • 5
    Spanos PK, Payne WS, Ivins JC, Pritchard DJ. Pulmonary resection for metastatic osteogenic sarcoma. J Bone Joint Surg [A]. 1976; 58: 624–628.
  • 6
    Telander RL, Pairolero PC, Pritchard DJ, Sim FH, Gilchrist GS. Resection of pulmonary metastatic osteogenic sarcoma in children. Surgery. 1978; 84: 335–341.
  • 7
    Rosenberg SA, Flye MW, Conkle D, Seipp CA, Levine AS, Simon RM. Treatment of osteogenic sarcoma. II. Aggressive resection of pulmonary metastases. Cancer Treat Rep. 1979; 63: 753–756.
  • 8
    Schaller RT, Haas J, Schaller J, Morgan A, Bleyer A. Improved survival in children with osteosarcoma following resection of pulmonary metastases. J Pediatr Surg. 1982; 17: 546–550.
  • 9
    Putnam JB, Roth JA, Wesley MN, Johnston MR, Rosenberg SA. Survival following aggressive resection of pulmonary metastases from osteogenic sarcoma: analysis of prognostic factors. Ann Thorac Surg. 1983; 36: 516–523.
  • 10
    Goorin AM, Delorey MJ, Lack EE, et al. Prognostic significance of complete surgical resection of pulmonary metastases in patients with osteogenic sarcoma: analysis of 32 patients. J Clin Oncol. 1984; 2: 425–431.
  • 11
    Carter SR, Grimer RJ, Sneath RS, Matthews HR. Results of thoracotomy in osteogenic sarcoma with pulmonary metastases. Thorax. 1991; 46: 727–731.
  • 12
    Goorin AM, Shuster JJ, Baker A, Horowitz ME, Meyer WH, Link MP. Changing pattern of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: results from the Multiinstitutional Osteosarcoma Study. J Clin Oncol. 1991; 9: 600–605.
  • 13
    Pastorino U, Gasparini M, Tavecchio L, et al. The contribution of salvage surgery to the management of childhood osteosarcoma. J Clin Oncol. 1991; 9: 1357–1362.
  • 14
    La Quaglia MP. The surgical management of metastases in pediatric cancer. Semin Pediatr Surg. 1993; 2: 75–82.
  • 15
    Tabone M-D, Kalifa C, Rodary C, Raquin M, Valteau-Couranet D, Lemerle J. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J Clin Oncol. 1994; 12: 2614–2620.
  • 16
    Ward WG, Mikaelian K, Dorey F, et al. Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol. 1994; 12: 1849–1858.
  • 17
    Heij HA, Vos A, de Kraker J, Voûte PA. Prognostic factors in surgery for pulmonary metastases in children. Surgery. 1994; 115: 687–693.
  • 18
    Temeck BK, Wexler LH, Steinberg SM, McClure LL, Horowitz M, Pass HI. Metastasectomy for sarcomatous pediatric histologies: results and prognostic factors. Ann Thorac Surg. 1995; 59: 1385–1390.
  • 19
    Saeter G, Høie J, Stenwig AE, Johannsson AK, Hannisdal E, Solheim Ø. Systemic relapse of patients with osteogenic sarcoma: prognostic factors in long term survival. Cancer. 1995; 75: 1084–1093.
    Direct Link:
  • 20
    Ferrari S, Bacci G, Picci P, et al. Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Ann Oncol. 1997; 8: 765–771.
  • 21
    Ellis PM, Tattersall MHN, McCaughan B, Stalley P. Osteosarcoma and pulmonary metastases: 15-year experience from a single institution. Aust N Z J Surg. 1997; 67: 625–629.
    Direct Link:
  • 22
    Bacci G, Ferrari S, Longhi A, et al. Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy. Eur J Cancer. 2001; 37: 32–38.
  • 23
    Weeden S, Grimmer RJ, Cannon SR, Taminiau AH, Uscinska BM. The effect of local recurrence on survival of resected osteosarcoma. Eur J Cancer. 2001; 37: 39–46.
  • 24
    McCarville MB, Kaste SC, Cain AM, Goloubeva O, Rao BN, Pratt CB. Prognostic factors and imaging patterns of recurrent pulmonary nodules after thoracotomy in children with osteosarcoma. Cancer. 2001; 91: 1170–1176.
    Direct Link:
  • 25
    Tsuchiya H, Kanazawa Y, Abdel-Wanis ME, et al. Effect of timing of pulmonary metastases identification on prognosis of patients with osteosarcoma: the Japanese Musculoskeletal Oncology Group Study. J Clin Oncol. 2002; 20: 3470–3477.
  • 26
    Ferrari S, Briccoli A, Mercuri M, et al. Post-relapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol. 2003; 21: 710–715.
  • 27
    Miser J, Arndt C, Smithson W, et al. Treatment of high-grade osteosarcoma (OGS) with ifosfamide (IFOS), MESNA (MES), Adriamycin (ADR), high-dose methotrexate (HDMTX), with or without cisplatin (CDDP); results of two pilot trials [abstract]. Proc Am Soc Clin Oncol. 1994; 13: 421a.
  • 28
    Arndt C, Miser J, Prichard D, et al. Treatment of high-grade osteosarcoma (OGS) with ifosfamide (IFOS), MESNA (MES), Adriamycin (ADR), high-dose methotrexate (HDMTX), and cisplatin (CDDP) [abstract]. Med Pediatr Oncol. 1996; 27: 227a.
  • 29
    Meyers P, Schwartz C, Bernstein M, et al. Addition of ifosfamide and muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate improves event free survival (EFS) in localized osteosarcoma (OS) [abstract]. Proc Am Soc Clin Oncol. 2001; 20: 367a.
  • 30
    Seibel N, Krailo M, Sato J, et al. Phase II window of topotecan in newly diagnosed metastatic osteosarcoma-CCG 7943 [abstract]. Proc Am Soc Clin Oncol. 2001; 20: 378a.
  • 31
    Nachman J, Simon M, Rubin C, Peabody T. Intensive pre-operative therapy with escalating doses of ifosfamide and carboplatin in conjunction with Adriamycin for patients with localized osteosarcoma [abstract]. Med Pediatr Oncol. 2001; 37: 176a.
  • 32
    Womer RB, Daller RT, Fenton JG, Miser JS. Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children. Eur J Cancer. 2000; 36: 87–94.
  • 33
    Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol. 1987; 5: 1191–1198.
  • 34
    Cairo MS, Shen V, Krailo MD, et al. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a Children's Cancer Group report. J Pediatr Hematol Oncol. 2001; 23: 30–38.
  • 35
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457–481.
  • 36
    Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: I-analysis and examples. Br J Cancer. 1977; 35: 1–39.
  • 37
    Anderson PM, Wiseman GA, Dispenzieri A, et al. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol. 2002; 20: 189–196.
  • 38
    Franzius C, Bielack S, Sciuk J, Vollet B, Jürgens H, Schober O. High activity samarium-152 EDTMP therapy in unresectable osteosarcoma. Nuklearmedizin. 1999; 38: 337–340.
  • 39
    Welsh JS, Thurman SA, Borzillary S, Schwartz CL, Howard SP. Sm-153 EDTMP for recurrent metastatic osteosarcoma. Clin Adv Hematol Oncol. 2003; 1: 181–183.
  • 40
    Kleinerman ES. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Hematol Oncol Clin North Am. 1995; 9: 927–938.
  • 41
    Anderson PM, Markovic SN, Sloan JA, et al. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin Cancer Res. 1999; 5: 2316–2323.
View Full Article (HTML) Get PDF (176K)